Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

J Am Soc Nephrol. 2014 Jun;25(6):1237-54. doi: 10.1681/ASN.2013070810.


Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, Thakur S, Fanti P, Szyndralewiez C, Barnes JL, Block K, Abboud HE.

Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1276-87. doi: 10.1152/ajprenal.00396.2014.


Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.

Jha JC, Thallas-Bonke V, Banal C, Gray SP, Chow BS, Ramm G, Quaggin SE, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Diabetologia. 2016 Feb;59(2):379-89. doi: 10.1007/s00125-015-3796-0.


Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.

Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM.

Clin Sci (Lond). 2013 Feb;124(3):191-202. doi: 10.1042/CS20120330.


Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, Brandes RP, Devaraj S, Török NJ.

Free Radic Biol Med. 2012 Jul 15;53(2):289-96. doi: 10.1016/j.freeradbiomed.2012.05.007.


Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy.

Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hébert RL.

Am J Physiol Renal Physiol. 2010 Dec;299(6):F1348-58. doi: 10.1152/ajprenal.00028.2010.


Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling.

Gray SP, Di Marco E, Kennedy K, Chew P, Okabe J, El-Osta A, Calkin AC, Biessen EA, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):295-307. doi: 10.1161/ATVBAHA.115.307012.


Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.

Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, Molango S, Heitz F, Merlot C, Szyndralewiez C, Page P, Brenner DA.

Hepatology. 2012 Dec;56(6):2316-27. doi: 10.1002/hep.25938.


Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.

Lan T, Kisseleva T, Brenner DA.

PLoS One. 2015 Jul 29;10(7):e0129743. doi: 10.1371/journal.pone.0129743.


Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques.

Xu S, Chamseddine AH, Carrell S, Miller FJ Jr.

Redox Biol. 2014 Apr 15;2:642-50. doi: 10.1016/j.redox.2014.04.004.


Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney.

Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE.

J Biol Chem. 2005 Nov 25;280(47):39616-26.


Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury.

Braunersreuther V, Montecucco F, Asrih M, Pelli G, Galan K, Frias M, Burger F, Quinderé AL, Montessuit C, Krause KH, Mach F, Jaquet V.

J Mol Cell Cardiol. 2013 Nov;64:99-107. doi: 10.1016/j.yjmcc.2013.09.007. Erratum in: J Mol Cell Cardiol. 2014 Jan;66:189. Ashri, Mohammed [corrected to Asrih, Mohamed].


Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases.

Eid AA, Gorin Y, Fagg BM, Maalouf R, Barnes JL, Block K, Abboud HE.

Diabetes. 2009 May;58(5):1201-11. doi: 10.2337/db08-1536.


NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis.

Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Circulation. 2013 May 7;127(18):1888-902. doi: 10.1161/CIRCULATIONAHA.112.132159.


Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease.

You YH, Quach T, Saito R, Pham J, Sharma K.

J Am Soc Nephrol. 2016 Feb;27(2):466-81. doi: 10.1681/ASN.2015030302.


Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina.

Deliyanti D, Wilkinson-Berka JL.

J Neuroinflammation. 2015 Jul 30;12:136. doi: 10.1186/s12974-015-0363-z.


Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.

Liu GC, Fang F, Zhou J, Koulajian K, Yang S, Lam L, Reich HN, John R, Herzenberg AM, Giacca A, Oudit GY, Scholey JW.

Diabetologia. 2012 Sep;55(9):2522-32. doi: 10.1007/s00125-012-2586-1.


Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.

Di Marco E, Gray SP, Chew P, Koulis C, Ziegler A, Szyndralewiez C, Touyz RM, Schmidt HH, Cooper ME, Slattery R, Jandeleit-Dahm KA.

Diabetologia. 2014 Mar;57(3):633-42. doi: 10.1007/s00125-013-3118-3.


Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes.

Maalouf RM, Eid AA, Gorin YC, Block K, Escobar GP, Bailey S, Abboud HE.

Am J Physiol Cell Physiol. 2012 Feb 1;302(3):C597-604. doi: 10.1152/ajpcell.00331.2011.


Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling.

Yong R, Chen XM, Shen S, Vijayaraj S, Ma Q, Pollock CA, Saad S.

PLoS One. 2013 Aug 26;8(8):e73428. doi: 10.1371/journal.pone.0073428.

Items per page

Supplemental Content

Support Center